Navigation Links
Protein level may serve as predictor of severe osteoarthritis
Date:7/29/2009

Osteoarthritis (OA), the most common joint disorder throughout the world and a leading cause of disability, is characterized by pain, impaired joint mobility, reduction of muscular strength and loss of joint function. Unlike most other common diseases, little is known about its origins, and factors predicting a severe disease course have not been identified. A new study, the first to establish a laboratory marker for the risk of severe OA, found that vascular cell adhesion molecule 1 (VCAM-1), was a strong predictor of hip and knee joint replacement due to severe OA. The study was published in the August issue of Arthritis & Rheumatism (http://www.interscience.wiley.com/journal/arthritis).

Led by Georg Schett of the University of Erlangen-Nuremberg in Erlangen, Germany, the study involved 912 healthy individuals in Bruneck, Italy, 60 of whom underwent hip or knee replacement surgery due to severe OA in a 15-year follow-up period. Subjects underwent a baseline exam in 1990 and followup exams were performed every five years until 2005. Blood samples were analyzed for VCAM-1, a sialoglycoprotein (a combination sugar and protein) expressed on cells in the cartilage and connective tissue.

The results showed that VCAM-1 levels were substantially elevated in the 60 individuals who underwent joint replacement, with the highest baseline levels seen in those who underwent bilateral joint replacement. "The level of VCAM-1 emerged as a significant predictor of the risk of joint replacement due to severe OA, equaling or even surpassing the effects of age," the authors state. They also note that inclusion of VCAM-1 levels in risk prediction models resulted in a more accurate classification of individuals.

VCAM-1 promotes leukocyte adhesion and homing to sites of inflammation. In chondrocytes (cartilage cells), VCAM-1 expression is induced by inflammatory cytokines (proteins released by immune system ells). The authors suggest that increased VCAM-1 levels may therefore mirror active cartilage damage or an inflammatory component in OA. Since it mediates the interaction of chondrocytes with immune cells, VCAM-1 may also contribute to immune-mediated cartilage damage.

Establishing laboratory biomarkers of severe OA is important for a number of reasons. The standard risk factors of age and weight are not enough for accurate risk prediction, and since OA is a highly prevalent disease, it would be helpful to accurately identify those at greater risk of developing rapid progression or severe disease. Early diagnosis would also be beneficial because the disease is present before clinical symptoms are present. Finally, improved prediction of severe OA would help identify patients for treatment interventions such as aerobic exercise, strength training and weight loss and might also help tailor therapeutic measures.

"Further clarification of the mechanism underlying the association between VCAM-1 level and OA may well contribute to a better understanding of disease etiology," the authors conclude, adding that application of their findings in routine clinical practice would require further studies to duplicate the results.


'/>"/>

Contact: Jennifer Beal
medicalnews@wiley.com
44-124-377-0633
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Protein Clumps May Appear Years Before Memory Problems
2. Human cells secrete cancer-killing protein, UK study finds
3. Cellular Protein Yields Clues to Diabetes, Alzheimers
4. Key Protein Might Shield Brain Cells
5. Brain Imaging (MRI/PET) and Measurements of Proteins in Spinal Fluid May Improve Alzheimers Prediction and Diagnosis
6. Fat-Cell Protein May Reduce Diabetes Risk
7. Cell Protein Could Help Spur Malignancy
8. UAB researchers draft 3-D protein map to aid stroke, cancer research
9. Marking anorexia with a brain protein
10. Lab Study Finds Protein That May Inhibit Cancer Spread
11. Fish protein link to controlling high blood pressure -- new study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 25, 2016 , ... Austin residents seeking Mohs surgery services, can now turn ... to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization ... selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
(Date:6/24/2016)... San Diego, CA (PRWEB) , ... June 24, 2016 , ... ... up with the American Cancer Society and the Road To Recovery® program to drive ... care to seniors and other adults to ensure the highest quality of life and ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions today ... cultivation and processing operations at its production facility, and opened its first two ... the manufacturer of a complete system of proactive air and surface purification solutions ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology: